Medicare GLP-1 Bridge Program: The Complete Guide
Starting July 1, 2026, Medicare is covering Wegovy, Zepbound, and Foundayo for weight loss at a fixed $50/month copay— no matter what Part D phase you're in. Here's exactly who qualifies, how to get it, and the fine print you need to know.
$50/mo
Fixed copay
all Part D stages
July 1, 2026
Program started
through Dec 2027
~13M
Eligible Medicare
beneficiaries
3 drugs
Covered
Wegovy · Zepbound · Foundayo
Important limitation: The $50 Bridge copay does not count toward your Part D deductible or your $2,100 annual out-of-pocket maximum. Extra Help / Low-Income Subsidy does not apply. See the Fine Print section below for full details.
What Is the Medicare GLP-1 Bridge Program?
The Medicare GLP-1 Bridge is a short-term demonstration program run by the Centers for Medicare & Medicaid Services (CMS). It runs from July 1, 2026 through December 31, 2027 and provides Medicare Part D enrollees access to specific GLP-1 weight loss medications at a capped $50 monthly copay.
For decades, Medicare was statutorily prohibited from covering weight loss drugs — the Social Security Act explicitly excluded them. GLP-1 medications for diabetes (Ozempic, Mounjaro) had always been covered because they treated a covered condition. But GLP-1s prescribed specifically for obesity and weight management faced a coverage wall.
The Bridge program is CMS's response to that gap. Rather than waiting for permanent legislation, CMS structured the Bridge as a demonstration to collect data, establish a coverage framework, and serve approximately 13 million eligible Medicare beneficiaries who have obesity without Type 2 Diabetes.
Who Qualifies: BMI and Comorbidity Requirements
Eligibility has two parts: a plan requirement and a clinical requirement. You must meet both to access the Bridge.
Plan Requirement (must have one of these)
- Standalone Medicare Part D Prescription Drug Plan (PDP)
- Medicare Advantage plan with drug coverage (MA-PD) — includes HMO, PPO, HMO-POS, and regional PPO plans
Original Medicare (Parts A + B only, no Part D) does not qualify
Clinical Requirement — BMI Tiers
No additional condition required
Qualifies automatically with documented BMI measurement
PLUS one of: Heart failure · Uncontrolled hypertension · Chronic kidney disease
Comorbidity must be documented in medical record with an active diagnosis code
PLUS one of: Pre-diabetes · Previous heart attack · Previous stroke · Symptomatic peripheral artery disease
Prior events (MI, stroke) count — diagnosis must be in your medical record
Type 2 Diabetes · Obstructive sleep apnea · MASH (fatty liver disease)
These conditions explicitly exclude you from the Bridge Program — different coverage pathways may apply
Which GLP-1 Drugs Are Covered?
Only three specific drugs are covered under the Bridge. The diabetes-indication versions of the same drugs are explicitly excluded.
| Drug | Bridge Covered |
|---|---|
Wegovy® Novo Nordisk | Yes |
Zepbound® Eli Lilly | Yes |
Foundayo® Eli Lilly | Yes |
Ozempic® Novo Nordisk | No |
Mounjaro® Eli Lilly | No |
Compounded GLP-1s 503A/503B pharmacies | No |
✅Wegovy®: All formulations covered — injection pens and the newer oral tablet form
✅Zepbound®: KwikPen formulation only. Single-dose vials are NOT covered under the Bridge
✅Foundayo®: New oral GLP-1 — the first non-injectable GLP-1 available under Medicare coverage
⚠️Ozempic®: NOT covered under Bridge — Ozempic is the diabetes indication. Wegovy (same drug, obesity indication) IS covered
⚠️Mounjaro®: NOT covered under Bridge — Mounjaro is the diabetes indication. Zepbound KwikPen (same drug, obesity indication) IS covered
⚠️Compounded GLP-1s: Compounded versions are explicitly excluded from the Bridge Program regardless of source
How to Sign Up: Step-by-Step
There is no separate enrollment form. Access flows through your existing Medicare Part D plan and a doctor's prescription. Here's exactly what to do.
Check your Medicare Part D plan
Confirm you are enrolled in a Medicare standalone prescription drug plan (PDP) or a Medicare Advantage plan with drug coverage (MA-PD). If you only have Original Medicare (Parts A and B) without Part D, you are not eligible for the Bridge. You can enroll in Part D during a Special Enrollment Period if you qualify.
Call 1-800-MEDICARE or log into medicare.gov to confirm your Part D enrollment
Confirm your BMI and comorbidities
Before your appointment, know your current BMI. If your BMI is between 27–34, identify which qualifying condition applies to you (pre-diabetes, prior heart attack/stroke, hypertension, CHF, CKD, or peripheral artery disease). Have recent lab work or medical records showing these diagnoses if possible.
Calculate your BMI at home or ask your doctor to document it at your next visit
Talk to your doctor — request the right drug for the right indication
Make an appointment with your primary care doctor, obesity medicine specialist, or cardiologist. Ask specifically about Wegovy, Zepbound (KwikPen), or Foundayo for weight management. Emphasize that you want coverage under the Medicare GLP-1 Bridge. Your doctor must prescribe under the weight management indication — not a diabetes or cardiovascular indication — for the Bridge to apply.
Say: 'I'd like to discuss the Medicare GLP-1 Bridge Program and whether I qualify for Wegovy or Zepbound KwikPen'
Your doctor submits prior authorization
Unlike standard Part D drugs, the Medicare GLP-1 Bridge uses a centralized CMS prior authorization process. Your provider submits the PA request through this system, documenting your BMI, qualifying condition, and the specific Bridge-eligible drug. The PA process typically takes 1–5 business days.
Ask your doctor's office to confirm they have submitted the Bridge-specific PA — not a standard Part D PA
Fill your prescription and pay $50
Once the prior authorization is approved, take your prescription to any in-network pharmacy. Your copay will be $50 regardless of which Part D phase you are in (deductible, initial coverage, or catastrophic). This $50 is fixed and does not vary by income or subsidy status.
Check that your pharmacy processes it as a Bridge claim — if they try to charge more, ask them to reprocess
Maintain documentation for renewals
Prior authorization approvals for the Bridge are typically issued for 12 months, then require renewal. Keep taking your medication consistently and attend follow-up appointments. Your doctor will need to document ongoing response to treatment for renewal. The Bridge program runs through December 31, 2027.
Set a reminder to contact your doctor's office one month before your PA expires to start the renewal
Official Resources
- Medicare website: Medicare.gov/glp1bridge
- Phone: 1-800-MEDICARE (1-800-633-4227) — TTY: 1-877-486-2048
- Medicare Plan Finder: Medicare.gov/plan-compare to verify your plan participates
The Fine Print: What Medicare Won't Highlight
The Bridge is a real and meaningful program — but it comes with limitations that can catch people off guard. Read these carefully before making treatment decisions.
$50 does not count toward your deductible or out-of-pocket max
This is the most important limitation. The $50 monthly Bridge copay is separate from standard Part D cost-sharing. It does not accumulate toward your $2,100 annual out-of-pocket limit or your Part D deductible. If you are simultaneously taking other medications that do count toward your out-of-pocket max, those still follow the normal rules.
Extra Help (Low-Income Subsidy) does not apply
If you receive Extra Help or the Low-Income Subsidy (LIS) that normally reduces your Part D copays, those subsidies do not apply to Bridge claims. All Bridge participants — regardless of income — pay the same $50 copay.
Program ends December 31, 2027
The Bridge is an 18-month demonstration, not permanent coverage. CMS has signaled intent to move toward permanent legislation, but that requires Congressional action. If you start medication under the Bridge, plan for potential coverage disruption in 2028 unless permanent legislation passes before then.
Type 2 Diabetes patients are excluded
If you have Type 2 Diabetes, you cannot access the Bridge even if you also have obesity. However, you likely already have access to Ozempic or Mounjaro under your Part D plan for the diabetes indication. If you have both diabetes and cardiovascular disease, ask your doctor about the cardiovascular risk-reduction pathway for Wegovy (SELECT trial).
Initiated before July 1, 2026? You may still qualify
If you were already on an eligible GLP-1 medication for weight management before the Bridge launched, you can still qualify — as long as you meet the BMI and comorbidity criteria at the time of therapy initiation. Ask your doctor to submit a Bridge PA for your existing prescription.
Zepbound single-dose vials are not covered
Only the Zepbound KwikPen is covered under the Bridge. The single-dose vials — which Lilly sells directly at lower list prices through LillyDirect — are excluded. If you were using vials through a direct program, you may want to ask your doctor about switching to the KwikPen formulation to access Bridge pricing.
Frequently Asked Questions
Can I use the Bridge if I don't have Type 2 Diabetes?
Yes — and that's actually the point. The Bridge was specifically designed to extend access to Medicare beneficiaries who need GLP-1 medications for obesity and weight management but don't have Type 2 Diabetes (which previously was the main coverage pathway). If you have obesity without diabetes, this is your primary Medicare coverage route.
What if my BMI is 33 with high blood pressure?
You qualify. The BMI ≥ 30 tier with uncontrolled hypertension covers you. Make sure your hypertension diagnosis is documented in your medical records with an active ICD-10 code (I10) and that your doctor includes this in the prior authorization documentation.
Can I use a manufacturer savings card with the Bridge copay?
No. Manufacturer savings cards (like Novo Nordisk's savings offer or Lilly's savings card) are designed for commercially insured patients and are not permitted to be used alongside government program benefits like Medicare. The $50 Bridge copay is your final cost.
What happens if my plan doesn't participate in the Bridge?
All Medicare Part D plans (standalone PDPs and MA-PD plans) are required to participate in the Bridge Program as it is a CMS demonstration. If your pharmacy or plan is telling you they don't participate, escalate the issue: call 1-800-MEDICARE and report the problem.
What happens to my coverage after December 2027?
The Bridge is a temporary demonstration. After December 31, 2027, CMS intends to pursue permanent coverage legislation. If the legislation does not pass, coverage would revert to pre-Bridge rules. Patients on the Bridge should discuss a contingency plan with their doctor in late 2027, including manufacturer assistance programs and commercial options.
Will I need a new prescription or prior authorization to use the Bridge if I'm already on Wegovy?
You need a Bridge-specific prior authorization even if you already have an active prescription. The Bridge PA is processed through a CMS centralized system, separate from any existing Part D PA. Ask your doctor's office to specifically reference the Medicare GLP-1 Bridge Program when submitting.
Does the Bridge cover the Wegovy oral tablet (rybelsus-style pill)?
Yes — all formulations of Wegovy are covered, including the newer oral semaglutide tablet formulation, not just the weekly injection pen. Foundayo (orforglipron) is a completely separate once-daily oral GLP-1 pill that is also covered.
I have pre-diabetes but not full diabetes — does that count?
Yes. Pre-diabetes (ICD-10 code R73.09 or R73.01) qualifies you under the BMI ≥ 27 tier. This is specifically listed as a qualifying condition, along with previous heart attack, stroke, and symptomatic peripheral artery disease. Make sure your pre-diabetes is documented in your chart.
After the Bridge: What Happens in 2028?
The Bridge Program is a temporary 18-month demonstration — not permanent law. CMS has signaled its intent to use the demonstration data to support permanent Medicare coverage of GLP-1 medications for obesity, but that requires legislation from Congress.
If you start a GLP-1 medication under the Bridge, plan now for the possibility that coverage could change after December 2027. Talk to your doctor about:
- Manufacturer patient assistance programs (NovoCare for Wegovy, Lilly Cares for Zepbound) if coverage lapses
- Telehealth-based GLP-1 programs that may offer competitive cash pricing
- Compounded GLP-1 options from 503B pharmacies if access is interrupted
- Whether permanent legislation passes before the Bridge expires
GLPMAXX will update this page as the program evolves. Bookmark it and check back before December 2027.
Getting the Most Out of Your GLP-1 Coverage
Accessing coverage is step one. Maximizing your results on medication is the ongoing work. GLP-1 medications work best when combined with the right nutrition approach, resistance training to preserve muscle, and consistent tracking.
Once You Have Coverage, Maximize the Results
The Bridge gets you the medication. GLPMAXX gives you the tools to get the most from it — macro targets adjusted for your goal weight, the MAXX resistance program to protect muscle mass, and injection tracking to stay consistent.